Q32 Bio (STU:DB0) EBIT: €28.79 Mil (TTM As of Mar. 2026)


STU:DB0 Q32 Bio Inc STU:DB0
17 GF Score
Price €9.65
! 2 Warning Signs
View Full Analysis

What is Q32 Bio EBIT?

Q32 Bio STU:DB0 -5.76% 17 EBIT is €28.79 Mil as of Mar. 2026. GuruFocus rates STU:DB0 with a GF Score™ of 17/100. The stock has 2 warning signs investors should review.

Q32 Bio's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-6.68 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €28.79 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Q32 Bio's annualized ROC % for the quarter that ended in Mar. 2026 was -203.39%. Q32 Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -522.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Q32 Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 21.55%.

Q32 Bio  (STU:DB0) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Q32 Bio's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-26.72 * ( 1 - 0% )/( (13.783 + 12.492)/ 2 )
=-26.72/13.1375
=-203.39 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=52.757 - 1.65 - ( 41.246 - max(0, 9.689 - 47.013+41.246))
=13.783

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=55.079 - 2.336 - ( 43.9 - max(0, 9.229 - 49.48+43.9))
=12.492

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Q32 Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-26.72/( ( (5.191 + max(-2.61, 0)) + (5.039 + max(-2.299, 0)) )/ 2 )
=-26.72/( ( 5.191 + 5.039 )/ 2 )
=-26.72/5.115
=-522.39 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.162) - (1.65 + 0 + 2.122)
=-2.61

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.916) - (2.336 + 0 + 0.879)
=-2.299

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Q32 Bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=28.785/133.546
=21.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio EBIT Related Terms

Q32 Bio EBIT Historical Data

* Premium members only.

The historical data trend for Q32 Bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q32 Bio EBIT Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
-32.47 -37.03 -44.25 -42.96 26.41

Q32 Bio Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.31 -7.97 -6.04 49.47 -6.68

STU:DB0 vs ABOS, TNYA, MDWD: EBIT Comparison

For the Biotechnology subindustry, Q32 Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Q32 Bio's EV-to-EBIT falls into.


STU:DB0
17GF Score
Q32 Bio Inc STU:DB0
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q32 Bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €28.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €28.79 Mil mean?
Q32 Bio (STU:DB0) has a EBIT of €28.79 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Q32 Bio.
Is Q32 Bio's EBIT too high?
Q32 Bio's current EBIT is €28.79 Mil. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's EBIT compare to ABOS and TNYA?
Q32 Bio's EBIT of €28.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Q32 Bio. Q32 Bio's current EBIT is €28.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (STU:DB0) has a current EBIT of €28.79 Mil. The current EBIT is €28.79 Mil. Q32 Bio's overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Q32 Bio (STU:DB0), the current EBIT is €28.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q32 Bio Business Description

Other Exchanges QTTB:USADB0:Germany
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for STU:DB0

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.65
Price